Cancer is one of the most dominant global health concerns, and the field of cancer therapeutics is in an era of rapid expansion. It is thus critical that the system for evaluating the effectiveness of new cancer treatments be accurate, standardized, and applied to clinical research across healthcare systems.
RECIST is a set of published rules that define when cancer patients with solid tumors “respond,” “stabilize,” or “progress” during treatments. Below is a summary of the current guidelines for the assessment of tumor response to antineoplastic therapies including special considerations such as evaluation of immune therapies and malignancies involving the central nervous system. Also reviewed are different assessment techniques and the rationalization of standardization of assessment systems.
Seymour L, Bogaerts J, Perrone A, et al. iRecist: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:143–52.CrossRefGoogle Scholar
Wolchok JD, Hoos A, O’Day S, et al. Guideline for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Cancer Therapy. 2009;15:7412–20.Google Scholar
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.CrossRefPubMedGoogle Scholar
ZinZani P, Tani M, Alinari S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17:1296–300.CrossRefPubMedGoogle Scholar
Wahl R, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122–50.CrossRefGoogle Scholar
Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–6.CrossRefPubMedGoogle Scholar
Bos R, van Der Hoeven JJ, van der WE, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.CrossRefPubMedGoogle Scholar
Cerfolio R, Bryant A, Winokur T, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903–9.CrossRefPubMedGoogle Scholar
Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059–66.PubMedGoogle Scholar
MacDonald DR, Cascino TL, Scold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.CrossRefPubMedGoogle Scholar
Wen P, Macdonald D, Reardon D, et al. Update response assessment criteria for hight-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.CrossRefGoogle Scholar
Lin N, Aoyama H, Barani I, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16:e270–8.CrossRefPubMedGoogle Scholar